These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26154432)

  • 1. Barriers to positive policy change that aims to increase access to medicines through reclassification: the case of oseltamivir in New Zealand.
    Shaw JP; Gauld N; Kelly F
    Int J Pharm Pract; 2016 Feb; 24(1):6-12. PubMed ID: 26154432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Australian pharmacy perspectives on increasing access to medicines through reclassification.
    Mey A; King M; Kelly F; Grant G; Townshend J; Baumann-Birkbeck L; Woods P; Hope D
    J Health Serv Res Policy; 2019 Apr; 24(2):81-90. PubMed ID: 30352516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacists' adoption into practice of newly reclassified medicines from diverse therapeutic areas in Scotland: a quantitative study of factors associated with decision-making.
    Paudyal V; Hansford D; Cunningham S; Stewart D
    Res Social Adm Pharm; 2014; 10(1):88-105. PubMed ID: 23665077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is non-prescription oseltamivir availability under strict criteria workable? A qualitative study in New Zealand.
    Gauld N; Kelly F; Shaw J
    J Antimicrob Chemother; 2011 Jan; 66(1):201-4. PubMed ID: 21051373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why does increasing public access to medicines differ between countries? Qualitative comparison of nine countries.
    Gauld N; Bryant L; Emmerton L; Kelly F; Kurosawa N; Buetow S
    J Health Serv Res Policy; 2015 Oct; 20(4):231-9. PubMed ID: 26152909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicines reclassification from a pharmaceutical industry perspective: An international qualitative study.
    Gauld NJ; Kelly FS; Emmerton LM; Kurosawa N; Bryant LJM; Buetow SA
    Res Social Adm Pharm; 2019 Apr; 15(4):387-394. PubMed ID: 30917892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-prescription medicines: current issues in Australian community pharmacy.
    Tan AC; Emmerton L
    Int J Pharm Pract; 2009 Aug; 17(4):207-13. PubMed ID: 20217945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysing the landscape for prescription to non-prescription reclassification (switch) in Germany: an interview study of committee members and stakeholders.
    Gauld NJ
    BMC Health Serv Res; 2019 Jun; 19(1):404. PubMed ID: 31221154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Australian pharmacists: ready for increased non-prescription medicines reclassification.
    Hope DL; Woods P; Mey A; Kelly FS; Townshend J; Baumann-Birkbeck LM; King MA
    Int J Pharm Pract; 2020 Jun; 28(3):246-254. PubMed ID: 31913550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance and uncertainty: community pharmacy responses to over the counter medicine abuse.
    Cooper R
    Health Soc Care Community; 2013 May; 21(3):254-62. PubMed ID: 23320510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality supply of nonprescription medicines in Portuguese community pharmacy: An exploratory case study.
    Veiga P; Lapão LV; Cavaco AM; Guerreiro MP
    Res Social Adm Pharm; 2015; 11(6):880-90. PubMed ID: 25662595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review in select countries of the role of the pharmacist in consultations and sales of non-prescription medicines in community pharmacy.
    van Eikenhorst L; Salema NE; Anderson C
    Res Social Adm Pharm; 2017; 13(1):17-38. PubMed ID: 27033426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over-the-counter prescribing and pharmacists' adoption of new medicines: diffusion of innovations.
    Paudyal V; Hansford D; Cunningham S; Stewart D
    Res Social Adm Pharm; 2013; 9(3):251-62. PubMed ID: 22835710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Views and experiences of community pharmacists and superintendent pharmacists regarding the New Medicine Service in England prior to implementation.
    Wells KM; Thornley T; Boyd MJ; Boardman HF
    Res Social Adm Pharm; 2014; 10(1):58-71. PubMed ID: 23608701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 'third class' of medications: Sales and purchasing behavior are associated with pharmacist only and pharmacy medicine classifications in Australia.
    Emmerton L
    J Am Pharm Assoc (2003); 2009; 49(1):31-7. PubMed ID: 19196594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community pharmacists' adoption of medicines reclassified from prescription-only status: a systematic review of factors associated with decision making.
    Paudyal V; Hansford D; Cunningham S; Stewart D
    Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):396-406. PubMed ID: 22362493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-to-consumer advertising: Australian pharmacists' experiences with non-prescription medicines.
    Chaar B; Kwong K
    Int J Pharm Pract; 2010 Feb; 18(1):43-50. PubMed ID: 20405595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expectations and responsibilities regarding the sale of complementary medicines in pharmacies: perspectives of consumers and pharmacy support staff.
    Iyer P; McFarland R; La Caze A
    Int J Pharm Pract; 2017 Aug; 25(4):292-300. PubMed ID: 27633447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacists' views on Indigenous health: is there more that can be done?
    Stoneman J; Taylor SJ
    Rural Remote Health; 2007; 7(3):743. PubMed ID: 17688377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacists' and consumers' viewpoints on counselling on prescription medicines in Australian community pharmacies.
    Puspitasari HP; Aslani P; Krass I
    Int J Pharm Pract; 2010 Aug; 18(4):202-8. PubMed ID: 20636671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.